Medicine & Life Sciences
Albuminuria
18%
Angiotensin Receptor Antagonists
21%
Angiotensin-Converting Enzyme Inhibitors
15%
Child
43%
Child Health
16%
Chronic Kidney Failure
18%
Chronic Renal Insufficiency
100%
Confidence Intervals
16%
Cost-Benefit Analysis
61%
Costs and Cost Analysis
14%
Creatinine
17%
Cystatin C
24%
Cytoplasm
13%
Disease Progression
12%
Donepezil
21%
Glomerular Filtration Rate
43%
Glucocorticoids
14%
Growth Hormone
15%
Health Care Outcome Assessment
19%
Hearing
14%
Hemorrhage
15%
Immunosuppressive Agents
14%
Inpatients
12%
Kidney
20%
Longitudinal Studies
13%
Multimedia
22%
Nephrotic Syndrome
96%
Non-Randomized Controlled Trials
20%
Outpatients
12%
Patient Reported Outcome Measures
53%
Patient Selection
18%
Pediatrics
14%
Pituitary Dwarfism
24%
Placebos
30%
Plasma Exchange
19%
Polyps
16%
Prednisolone
97%
Quality of Life
28%
Quality-Adjusted Life Years
27%
Random Allocation
14%
Randomized Controlled Trials
97%
Recurrence
33%
Renin-Angiotensin System
18%
Respiratory Tract Infections
45%
Sensorineural Hearing Loss
18%
Steroids
63%
Sudden Hearing Loss
21%
Therapeutics
22%
Uterine Hemorrhage
18%
Vasculitis
16%
Social Sciences
adverse events
8%
Child health
16%
childhood
13%
confidence
10%
costs
19%
death
11%
economics
13%
end stage renal disease
24%
evaluation
14%
Group
7%
health
5%
Healthcare
5%
inpatient treatment
23%
life years
20%
management
8%
quality of life
20%
relapse
15%
time
8%